Lupin Signs Distribution Agreements in Key EU Territories for Orphan Drug NaMuscla®

Zug, Switzerland, June 3 (Korea Bizwire) - Lupin is pleased to announce that it has entered into distribution agreements with three companies for its orphan drug NaMuscla® (mexiletine). Exeltis Healthcare S.L, Cresco Pharma B.V and Macure Pharma ApS will commercialize NaMuscula® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain [...]